Search Results for "C Myc Gene Colon Cancer"
Original Source: Evaluating markers for treatment selection based on survival time.
For many medical conditions, several treatment options may be available for treating patients. We consider evaluating markers based on a simple treatment selection policy that incorporates information on the patient's marker value. For example, colon cancer patients may be treated by surgery alone or surgery plus chemotherapy. The c-myc gene expression level may be used as a biomarker for treatment selection. Although traditional regression methods may assess the effect of the marker and treatment on outcom...
Matching Channels
Colon or Colorectal cancer is the growth of malignant polyps on the colon, bowel, anus and rectum. Growths in these locations can be benign, and removed by colonoscopy, but they have a risk of becom...
Polyps of the Colon and Rectum
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example,...
APC stands for adenomatous polyposis coli, a form of colorectal cancer and is a tumour suppressor
APC stands for adenomatous polyposis coli, a form of colorectal cancer and is a tumour suppressor. When APC it mutated, it can cause this particular type of colorectal cancer. When not present in it...
Matching News
Old drug, new tricks: aspirin may boost colon cancer survival for patients with gene mutation
Regular use of aspirin may extend the lives of colon cancer patients whose tumour carries a specific gene mutation, scientists report...
Oncotype DX Predicts Risk of Colon Cancer Recurrence
Among patients with Stage II or Stage III colon cancer, the Oncotype DX colon cancer test provides information about risk of cancer recurrence and overall survival, and may help guide treatment decisi...
Vast Gene Study Raises Hopes for Colon Cancer Drugs
Researchers have found genetic weak spots in colon cancer tumors that could lead to potent treatments, signaling hope against a cancer that is now almost always fatal once it spreads.
Oncotype DX Predicts Recurrence Risk in Stage II and Stage III Colon Cancer
Among patients with Stage II or Stage III colon cancer, the Oncotype DX colon cancer test provides information about risk of cancer recurrence and may help guide treatment decisions. These results wer...
Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predictin...
Agendia Launches ColoPrint for Colon Cancer
Agendia’s Microarray-based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II Colon Cancer Patients.
Study shows colon and rectal tumors constitute a single type of cancer
(NIH/National Cancer Institute) The pattern of genomic alterations in colon and rectal tissues is the same regardless of anatomic location or origin within the colon or the rectum, leading researchers...
Colon and rectal tumors constitute a single type of cancer, study shows
The pattern of genomic alterations in colon and rectal tissues is the same regardless of anatomic location or origin within the colon or the rectum, leading researchers to conclude that these two canc...
Matching PubMed Articles
The Role of NF-kappaB in Colon Cancer.
Colon cancer is the 3rd common malignancy and 4th common cause of cancer death in Korea. Recent studies have shown that abnormal inflammatory response plays a critical role in colon carcinogenesis. A...
BACKGROUND: Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and to...
Variation in the CYP19A1 gene and risk of colon and rectal cancer.
CYP19A1, or aromatase, influences estrogen-metabolizing enzymes and may influence cancer risk. We examine variation in the CYP19A1 gene and risk of colorectal cancer using data from population-based c...
Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer.
Programmed death-1 (PD-1), expressed by activated T cells, is a negative regulator of T lymphocytes. The associations of the immune response-related genes with cancer have been demonstrated. In this s...
Impact of Phytolacca americana Extracts on Gene Expression of Colon Cancer Cells.
Native Americans have used Phytolacca americana to treat breast ailments, gastrointestinal disorders, rashes, and inflammation. Some anti-cancer and anti-viral research has been reported on this peren...
